Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03684655 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Imaging Immune Activation in HIV by PET-MR

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 24, 2024 (before its estimated October 1, 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Phase: Phase 1 to Phase 2v8 Show 4 more changesShow less
    • Primary completion date: Oct 1, 2024 to Oct 1, 2025
    • Study completion date: Nov 1, 2024 to Nov 1, 2025
    • Site contact updated
    • Eligibility criteria expanded, about 1 word
  2. Primary completion date: Oct 1, 2023 to Oct 1, 2024
    • Study completion date: Oct 1, 2024 to Nov 1, 2024
    v7
  3. Re-verified, no change to tracked fieldsv6
  4. Primary completion date: Oct 1, 2021 to Oct 1, 2023
    • Study completion date: Oct 1, 2021 to Oct 1, 2024
    v5
  5. Lead sponsor: University of California, San Francisco to CellSight Technologies, Inc.
    • Collaborators: 1 to 2
    v4
Show 2 earlier versionsHide 2 earlier versions
  1. Primary completion date: Oct 1, 2020 to Oct 1, 2021
    • Study completion date: Jun 1, 2021 to Oct 1, 2021
    v3
  2. Primary completion date: Oct 1, 2019 to Oct 1, 2020
    • Study completion date: Jun 1, 2020 to Jun 1, 2021
    • Eligibility criteria expanded, about 265 words
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a single center exploratory imaging study involving one intravenous microdose of \[18F\]F-AraG followed by whole-body positron emission tomography-magnetic resonance (PET-MR) imaging in HIV infected individuals to determine the anatomical distribution of the PET tracer. Participants will be enrolled if they were treated during early or late HIV infection. In addition, individuals not on antiretroviral therapy (ART) or with HIV-1 plasma RNA levels \>5,000 copies/mL will be enrolled. Up to 30 participants will be enrolled with HIV.
Trial Details
NCT Number NCT03684655
Lead Sponsor CellSight Technologies, Inc.
Collaborators: National Institute of Allergy and Infectious Diseases (NIAID), University of California, San Francisco
Conditions
(from sponsor)		 HIV Infections
Related terms HIV Infections
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov